Novartis AG
Change company Symbol lookup
Select an option...
NVS Novartis AG
FRBA FIRST BANK (Hamilton)
UNM Unum Group
LLY Eli Lilly and Co
BDC Belden Inc
TTM Tata Motors Ltd
HOG Harley-Davidson Inc
SKY Skyline Champion Corp
MMM 3M Co
MPX Marine Products Corp
Go

Health Care : Pharmaceuticals | Large Cap Value
Based in Switzerland
Company profile

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines researches, develops, manufactures, distributes and sells patented prescription medicines to develop health outcomes for patients and healthcare providers. Sandoz develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical active substances that are not protected by valid and enforceable third-party patents. Alcon researches, develops, manufactures, distributes and sells eye care products. Alcon is a provider of eye care with product offerings in eye care devices and vision care. The Company's range of products includes pharmaceuticals and oncology medicines, generic and biosimilar medicines, and eye care devices.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Price
Delayed
$79.13
Day's Change
-1.82 (-2.25%)
Bid
--
Ask
--
B/A Size
--
Day's High
79.72
Day's Low
78.58
Volume
(Heavy Day)

Today's volume of 630,286 shares is on pace to be much greater than NVS's 10-day average volume of 1,640,966 shares.

630,286

Moore Kuehn Encourages MXIM, CGIX, PTI, and DCOM Investors to Contact Law Firm

10:59 am ET August 27, 2020 (Globe Newswire) Print

Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may ultimately seek increased consideration, additional disclosures, or other relief and benefits on behalf of the shareholders of these companies:

A registration statement was recently filed with the SEC regarding Analog Devices, Inc.'s acquisition of Maxim Integrated, which may omit material information regarding the financial metrics and analyses used to evaluate the merger. Under the proposed transaction, shareholders of Maxim will 0.630 of a share of Analog for every share owned.

-- Cancer Genetics, Inc. (NASDAQ: CGIX)

Cancer Genetics has agreed to merge with StemoniX. Under the proposed transaction, Cancer Genetics will issue shares of common stock to the owners of StemoniX, with current holders of Cancer Genetics common stock controlling only 22% of the combined company.

-- Proteostasis Therapeutics, Inc (NASDAQ: PTI)

Proteostasis Therapeutics has agreed to merge with Yumanity Therapeutics. Under the proposed transaction, current holders of Proteostasis Therapeutics common stock will only control 32.5% of the combined company.

-- Dime Community Bancshares, Inc. (NASDAQ: DCOM)

Dime has signed an agreement to merge with Bridge Bancorp, Inc. Under the proposed transaction, shareholders of Dime will receive 0.6480 shares of Bridge Bancorp for every share owned.

Moore Kuehn is investigating whether the Boards of the above companies 1) acted to maximize shareholder value, 2) failed to disclose material information, and 3) conducted a fair process.

Moore Kuehn encourages shareholders who would like to discuss their rights to contact Justin Kuehn, Esq. by email at jkuehn@moorekuehn.com or telephone at (212) 709-8245. The consultation and case are free with no obligation to you. Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

Moore Kuehn is a 5-star New York City-based law firm with attorneys representing investors and consumers in class action litigation involving securities law violations, financial fraud, breaches of fiduciary duties, and other claims. For additional information about Moore Kuehn, please go to http://www.moorekuehn.com/practice/new-york-securities-litigation/.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts:

Moore Kuehn, PLLC

Justin Kuehn, Esq.

30 Wall Street, 8 Floor

New York, New York 10005

jkuehn@moorekuehn.com

(212) 709-8245

https://ml.globenewswire.com/media/d193dca2-d2bd-436c-84ad-702f7e967f18/small/moorekuehn-1-png.png

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.